| Author | Year | Study design | Target population | NS form | Dose/day | Duration | Gender | Age | Sample size | Outcome | Jadad score |
| Hadi et al. [14] | 2018 | Randomized, double-blind, placebo-controlled trial | DM type 2 | Oil capsule | 500 mg | 8 weeks | Female | 30–60 | 43 | MDA, SOD, TNF-α, IL-1β, CAT, NO | 3 |
| Hadi et al. [13] | 2016 | Randomized, double-blind, placebo-controlled trial | Rheumatoid arthritis | Oil capsule | 500 mg | 8 weeks | Female | 20–50 | 39 | MDA, TAC, SOD, TNF-α, IL-10, CAT, NO | 4 |
| Kaatabi et al. [17] | 2015 | Randomized, participant blind, placebo-controlled trial | DM type 2 | Powder capsule | 2 gr | 48 weeks | Both | 18–60 | 114 | TAC, SOD, FBG, HbA1c, C-peptide, insulin resistance, beta-cell activity, CAT, glutathione, TBARS | 3 |
| Nikkhah-Bodaghi et al. [16] | 2019 | Randomized, double-blind, placebo-controlled trial | Ulcerative colitis | Powder capsule | 500 mg | 6 weeks | Both | >18 | 48 | MDA, TAC, TNF-α, hs-CRP, NFkB | 4 |
| Namazi et al. [15] | 2015 | Randomized, double-blind, placebo-controlled trial | Obese | Oil capsule | 3 gr | 8 weeks | Female | 25–50 | 49 | MDA, TAC, SOD, GPx | 4 |
|
|